PMC9358450_01
Breast presence of FLT3 ITD was documented by PCR and agarose gel electrophoresis (Kit LeukoStrat FLT3 Mutation Assay- Gel detection, Invivoscribe).
gr1.jpg
PMC9358450_01_gr1.jpg
fig0001
Breast presence of FLT3 ITD was also documented by PCR and agarose gel electrophoresis (Kit LeukoStrat FLT3 Mutation Assay- Gel detection, Invivoscribe) as shown in Fig.1.
PT TC before treatment with Gilteritinib. B: PT TC after treatment with Gilteritinib.
gr2.jpg
PMC9358450_01_gr2.jpg
fig0002
FLT3 inhibitor at a dosage of 80 mg/ day, as maintenance therapy. Fig. 2A and 2B respectively show the PT-TC breast images before and after Gilteritinib treatment.